These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17920529)

  • 1. Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor.
    Saita Y; Kondo M; Shimizu Y
    Int Immunopharmacol; 2007 Dec; 7(12):1528-34. PubMed ID: 17920529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
    Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
    Seibert C; Ying W; Gavrilov S; Tsamis F; Kuhmann SE; Palani A; Tagat JR; Clader JW; McCombie SW; Baroudy BM; Smith SO; Dragic T; Moore JP; Sakmar TP
    Virology; 2006 May; 349(1):41-54. PubMed ID: 16494916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human.
    Napier C; Sale H; Mosley M; Rickett G; Dorr P; Mansfield R; Holbrook M
    Biochem Pharmacol; 2005 Dec; 71(1-2):163-72. PubMed ID: 16298345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
    Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors.
    Hu Q; Huang X; Shattock RJ
    J Gen Virol; 2010 Dec; 91(Pt 12):2965-73. PubMed ID: 20810746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CCR5 receptor antagonists on endocytosis of the human CCR5 receptor in CHO-K1 cells.
    Longden J; Cooke EL; Hill SJ
    Br J Pharmacol; 2008 Apr; 153(7):1513-27. PubMed ID: 18223665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue: ROLE OF ILE198.
    Lau G; Labrecque J; Metz M; Vaz R; Fricker SP
    J Biol Chem; 2015 Apr; 290(17):11041-51. PubMed ID: 25767113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors.
    Billick E; Seibert C; Pugach P; Ketas T; Trkola A; Endres MJ; Murgolo NJ; Coates E; Reyes GR; Baroudy BM; Sakmar TP; Moore JP; Kuhmann SE
    J Virol; 2004 Apr; 78(8):4134-44. PubMed ID: 15047829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic mouse expressing human CCR5 as a model for in vivo assessments of human selective CCR5 antagonists.
    Saita Y; Kondo M; Miyazaki T; Yamaji N; Shimizu Y
    Eur J Pharmacol; 2005 Aug; 518(2-3):227-33. PubMed ID: 16076464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor.
    Watson C; Jenkinson S; Kazmierski W; Kenakin T
    Mol Pharmacol; 2005 Apr; 67(4):1268-82. PubMed ID: 15644495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.
    Rossi R; Lichtner M; De Rosa A; Sauzullo I; Mengoni F; Massetti AP; Mastroianni CM; Vullo V
    Clin Exp Immunol; 2011 Nov; 166(2):184-90. PubMed ID: 21985364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
    Nakata H; Kruhlak M; Kamata W; Ogata-Aoki H; Li J; Maeda K; Ghosh AK; Mitsuya H
    Antivir Ther; 2010; 15(3):321-31. PubMed ID: 20516552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5.
    Nishikawa M; Takashima K; Nishi T; Furuta RA; Kanzaki N; Yamamoto Y; Fujisawa J
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4708-15. PubMed ID: 16251315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
    Kang Y; Wu Z; Lau TC; Lu X; Liu L; Cheung AK; Tan Z; Ng J; Liang J; Wang H; Li S; Zheng B; Li B; Chen L; Chen Z
    J Biol Chem; 2012 May; 287(20):16499-509. PubMed ID: 22447925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR5 as a treatment target in pulmonary arterial hypertension.
    Amsellem V; Lipskaia L; Abid S; Poupel L; Houssaini A; Quarck R; Marcos E; Mouraret N; Parpaleix A; Bobe R; Gary-Bobo G; Saker M; Dubois-Randé JL; Gladwin MT; Norris KA; Delcroix M; Combadière C; Adnot S
    Circulation; 2014 Sep; 130(11):880-891. PubMed ID: 24993099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
    Zheng Y; Han GW; Abagyan R; Wu B; Stevens RC; Cherezov V; Kufareva I; Handel TM
    Immunity; 2017 Jun; 46(6):1005-1017.e5. PubMed ID: 28636951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment.
    Melikyan GB; Platt EJ; Kabat D
    Retrovirology; 2007 Aug; 4():55. PubMed ID: 17686153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).
    Garcia-Perez J; Rueda P; Alcami J; Rognan D; Arenzana-Seisdedos F; Lagane B; Kellenberger E
    J Biol Chem; 2011 Sep; 286(38):33409-21. PubMed ID: 21775441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.